Zoetis Inc. (NYSE:ZTS) Shares Sold by Virtue Capital Management LLC

by · The Cerbat Gem

Virtue Capital Management LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 8.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,185 shares of the company’s stock after selling 205 shares during the quarter. Virtue Capital Management LLC’s holdings in Zoetis were worth $427,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp increased its position in Zoetis by 0.5% during the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after buying an additional 95,856 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after acquiring an additional 185,364 shares during the last quarter. Mizuho Securities USA LLC increased its position in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. Bank of New York Mellon Corp increased its position in Zoetis by 4.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock worth $812,695,000 after purchasing an additional 178,303 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Zoetis by 5.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after purchasing an additional 194,542 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. Stifel Nicolaus raised their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. UBS Group assumed coverage on shares of Zoetis in a research note on Monday. They issued a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $216.70.

Check Out Our Latest Analysis on ZTS

Zoetis Stock Performance

Zoetis stock opened at $177.17 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a market cap of $79.93 billion, a price-to-earnings ratio of 33.30, a price-to-earnings-growth ratio of 2.89 and a beta of 0.89. The stock’s 50-day moving average is $181.37 and its 200-day moving average is $181.16.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the previous year, the company posted $1.36 earnings per share. Zoetis’s revenue was up 11.6% compared to the same quarter last year. Equities analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st were paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend was Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).